Intelligence / B2B SaaS / Acquisitions / Pacira BioSciences, Inc.
M&Acompleted an acquisition (SEC 8-K)17 Nov 2026
Pacira BioSciences, Inc.
17 Nov 2026: Completed an acquisition (SEC 8-K) · Pharma and biotech. Recorded in the SEC EDGAR full-text search.
- Filed
- 17 Nov 2026
- Ticker
- PCRX
- Role
- Completed an acquisition
- Sector
- Pharma and biotech
- Sic
- 2834
- Items
- 1.01, 1.02, 2.01, 2.04, 3.01, 3.03, 5.01, 5.02, 5.03, 7.01, 9.01
- Summary
- As previously disclosed, pursuant to the Merger Agreement, on October 30, 2026, Purchaser commenced a tender offer to acquire all of the outstanding shares of common stock of the Company, $0.001 par value per share (the "Shares"), at an offer price of $36.50 per Share in cash, net of applicable withholding taxes and wi
- Location
- Brisbane, CA
- State
- California
- Country
- United States
- SEC CIK
- 1396814
- Reference
- 0001140361-26-044354
What this signal means
Integration means consolidating tools and vendors: the buyer re-platforms the target, and an acquired company's stack is reviewed by its new owner.
- Completed an acquisition leads with 189 of 292, then Sold assets or a business (82).
- 103 added in the 30 days to 19 Nov 2026.
Reach them with AOS
Find the decision makers at Pacira BioSciences, Inc.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this m&a signal, for your approval.
More in Completed an acquisition
Acquisitions
18 NovAI Era Corp.completed an acquisition (SEC 8-K) · Real estate and investmentM&A18 NovSoundthinking, INC.completed an acquisition (SEC 8-K) · Software and ITM&A17 NovGridAI Technologies Corp.completed an acquisition (SEC 8-K) · Energy and utilitiesM&A17 NovInteger Holdings Corpcompleted an acquisition (SEC 8-K) · Medical devicesM&A17 NovViatris Inccompleted an acquisition (SEC 8-K) · Pharma and biotechM&A16 NovAon plccompleted an acquisition (SEC 8-K) · InsuranceM&A
Source: SEC EDGAR full-text search, data to 19 Nov 2026. Every Form 8-K reporting Item 2.01 (completion of an acquisition or disposition of assets) filed with the SEC in the last 90 days. The role (buyer, company acquired, seller) is read from the filing's own wording, which is quoted on each row. AOS shows what the public record says; it does not verify or endorse the company.